z-logo
Premium
Anti‐apoptotic effect of vinpocetine on cisplatin‐induced hepatotoxicity in mice: The role of Annexin‐V, Caspase‐3, and Bax
Author(s) -
Habib Sally A.,
Abdelrahman Rehab S.,
Abdel Rahim Mona,
Suddek Ghada M.
Publication year - 2020
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.22555
Subject(s) - vinpocetine , pharmacology , oxidative stress , apoptosis , inflammation , annexin , liver injury , chemistry , caspase 3 , medicine , immunology , programmed cell death , biochemistry
Hepatic damage is one of the most common complications related to cisplatin (Cis) use. Recently, liver protection lines are being discovered to avoid hepatic cell death as a result of oxidative, inflammatory, and apoptotic disturbance. Limited data reported the hepatoprotective effect of vinpocetine (Vin) in acute liver injury models. This study was designed to determine the potential protective effect of Vin (10‐30 mg/kg, orally) against Cis‐induced liver injury (10 mg/kg, IP) in mice. Vin administration for 1 week before Cis injection until the end of the experiment. On the 6th day after Cis injection, mice were anesthetized, blood and tissue samples were collected. Hepatic function, histological changes, oxidative stress, inflammation, and apoptotic markers were investigated. Vin administration ameliorated liver injury as indicated by decreased liver injury parameters; serum aminotransferases, ALK‐P, GGT, and bilirubin, restored the anti‐oxidant status by decrease MDA and NO x , and increased GSH and SOD, inhibited inflammation (IL‐6, TNF‐α, NFκB‐p65, and iNOS) and apoptosis (Annexin‐V, Bax, and Caspase‐3) parameters. Vin confers dose‐dependent protection against Cis‐induced liver injury. The hepatoprotective effect of Vin involved anti‐oxidative, anti‐inflammatory, and anti‐apoptotic activities.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here